Human milk oligosaccharides (HMOs) are a group of complex carbohydrates that are highly
abundant in human milk and contribute to shaping the infant’s gut microbiome and immune system for immediate and long-term health benefits.

Human milk oligosaccharides (HMOs) are the third most abundant component of human milk excluding water. Its concentration ranges from 5 to 15 g/L in mothers’ milk and has implications in wide-ranging health outcomes of the new-born.

2’FL and LNnT are among the most studied HMOs with clinical evidence to support
immunity and the developing microbiome. Latest research on additional HMOs in human milk & beyond show promise in expanded benefits on gut, immune, brain and bone health.

Currently there is scientific evidence linking HMOs and more particularly 2 FL and LNnT
with the prevention of allergic sensitization. The results both from preclinical and clinical
observational data, from the LIFE Child Cohort, demonstrates a positive effect of 2FL and
LNnT in reduction of allergic sensitization.

HMOs stimulate the development of a bifidogenic microbiome, which is boosting
a maturation of the immune system into a balanced TH1/TH2 development resulting
in a reduced risk of allergic disease.